Yuhan announced that it has become Samsung Bioepis' exclusive partner to market two of the latter's biosimilars in Korea, The Korea Herald reported Wednesday.
In the deal, Yuhan will biosimilars referencing Enbrel and Remicade.
Merck & Co. previously sold the drugs, which are marketed under the names Brenzys and Renflexis, respectively.
Merck will continue to market the drugs in the US and Europe.
To read more NewsPoints articles, click here.